Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Trends Are Creating New Opportunities For Industry Leaders
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Revenue Outlook: What CAGR Is Expected Through 2030?
The pharmaceutical CDMO market for formulations has experienced strong growth in recent years, increasing from $54.73 billion in 2025 to $60.7 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.9%. Several factors drove this expansion in the historical period, including a scarcity of specialized peptide API manufacturers, a reliance on in-house peptide production, an expanding pipeline of peptide therapeutics, stricter regulatory compliance demands, and the utilization of basic chemical synthesis techniques.
The market for pharmaceutical contract development and manufacturing organizations (CDMOs) specializing in formulations is projected to experience significant expansion in the coming years. By 2030, it is anticipated to reach $90.76 billion, reflecting a compound annual growth rate (CAGR) of 10.6%. This forecasted growth is driven by factors such as progress in custom peptide synthesis technologies, the broadening of commercial-scale GMP manufacturing, heightened outsourcing to CROs and SMEs, the creation of lifecycle management and process optimization approaches, and a growing need for clinical and preclinical peptide API production. Key trends shaping this period include an increased tendency to outsource peptide API manufacturing to contract producers, a rise in GMP-grade output for both clinical and commercial supply, greater demand for custom peptide synthesis and purification services, the broadening of peptide therapeutic pipelines across pharmaceutical firms, and an emphasis on process optimization and lifecycle management for peptide APIs.
Download A Free Sample Report For Comprehensive Market Insights:
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Development Factors: Which Trends Are Supporting Demand?
The anticipated expansion of the pharmaceutical contract development and manufacturing organization (CDMO) market for formulations is being driven by the rising volume of drug development and manufacturing activities. These activities involve the intensified efforts of pharmaceutical and biopharmaceutical firms to research, develop, and produce new medications. This surge is largely attributed to the growing worldwide demand for innovative and effective therapies, prompting companies to broaden their development pipelines and accelerate manufacturing schedules. A pharmaceutical CDMO supports drug development by designing and refining dosage forms, conducting stability assessments, and ensuring adherence to regulatory standards. It also oversees scale-up and production processes, facilitating quicker and more cost-effective product introductions. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a trade association headquartered in Belgium representing Europe’s pharmaceutical sector, reported that total pharmaceutical production in Europe reached $422,803 million (€390,000 million) in 2023, compared to $393,857 million (€363,300 million) in 2022. Consequently, the growth in drug development and manufacturing activities is propelling the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market forward.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Segment Analysis And Revenue Opportunities
The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market covered in this report is segmented –
1) By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Other Dosage Forms
2) By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology
3) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Users
Subsegments:
1) By Oral Solids: Tablets, Capsules, Granules, Powders, Modified-Release Formulations
2) By Oral Liquids: Syrups, Suspensions, Solutions, Emulsions, Elixirs
3) By Injectables: Vials, Ampoules, Prefilled Syringes, Lyophilized Injections, Injectable Emulsions
4) By Topicals: Creams, Ointments, Gels, Lotions, Foams,
5) By Inhalation Products: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizer Solutions, Nasal Sprays, Inhalation Capsules
6) By Transdermal And Patches: Matrix Patches, Reservoir Patches, Drug-In-Adhesive Patches, Microneedle Patches, Iontophoretic Patches
7) By Other Dosage Forms: Suppositories, Ophthalmic Preparations, Buccal Tablets, Sublingual Tablets, Implants
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the pharmaceutical CDMO sector for formulations are increasingly prioritizing the development of cutting-edge tools, including biologic formulation platforms, aimed at improving drug stability and shortening the time required to bring complex biologic therapies to market. These platforms are intricate systems engineered to produce stable, efficient formulations for biologic drugs, carefully adjusting variables like pH, excipients, and delivery mechanisms to ensure optimal stability, bioavailability, and safety throughout a product’s lifecycle. A notable example comes from June 2025, when WuXi Biologics, a contract research, development, and manufacturing organization based in China, introduced WuXiHigh 2.0—a next-generation platform for high-concentration formulations. This system supports biologic formulations with protein levels reaching 230 mg/mL, exceeding the current FDA-approved maximum of 200 mg/mL, while also slashing viscosity by as much as 90% thanks to proprietary excipient combinations and high-throughput tools. By tackling major hurdles in high-concentration biologic development, such as viscosity and aggregation, it enhances injection efficiency, patient adherence, and manufacturing success during both clinical trials and commercial production.
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Leading Players Shaping Industry Direction
Major companies operating in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, Aarti Pharmalabs Limited.
Access The Complete Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Report:
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Geographic Landscape: Which Region Dominates Industry Growth?
Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
